Allogene Therapeutics, Inc.

NASDAQ:ALLO

Biotechnology

Healthcare
$0.70 +1.02%

+$0.02 today

Market cap
$241.11M
Beta
0.46
P/E (TTM)
-2.7
EPS (TTM)
-$0.72
52W Low $0.98High $4.46

Volume 10.55M

Average 10.19M

ALLO Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

Allogene Therapeutics, Inc.NASDAQ: ALLO

Operating Margin · Q1 FY2026 · quarter ended Mar 2026

Operating margin not reported for Q1 FY2026

Context

  • Operating margin widened in 0 of the last 2 fiscal years.
  • FY2024 was the lowest level in the 3 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
—— QoQ
Last fiscal yearDec 2025
—— YoY
LTMMar 2026
—— YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2024
-1241813.6%
Year-over-year change
-896827.3pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Margin vs competitors

How ALLO compares with its peers on the latest reported figures

ALLO Competitors Peer median
Operating Margin for ALLO and competitors
Company Period LTM level YoY 3-year change
IPSCCentury Therapeutics, Inc.FY2025-13.8% +2082.7 pp+2560.4 pp
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026-27.3% -20.6 pp+470.9 pp
CLLSCellectis S.A.LTM Mar 2026-67.6% +43.4 pp+422.4 pp
DTILPrecision BioSciences, Inc.LTM Mar 2026-86.8% -0.6 pp+96.1 pp
CELUCelularity Inc.LTM Dec 2025-230.9% -160.2 pp-88.5 pp
AUTLAutolus Therapeutics plcLTM Mar 2026-285.9% +4535.6 pp+1934.5 pp
CRBUCaribou Biosciences, Inc.LTM Mar 2026-1175.7% +473.1 pp-452.3 pp
FATEFate Therapeutics, Inc.LTM Mar 2026-2207.5% -704.0 pp-1902.2 pp
ALLOAllogene Therapeutics, Inc.FY2025— ——
Peer median (excluding ALLO) -158.8%+21.4 pp+259.2 pp

Competitors are the stored peer set for ALLO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue114.09M156K95K22K0
Cost of Revenue014.3M0012.36M
Gross Profit114.09M(14.14M)95K22K(12.36M)
Gross Margin100.0%-9063.5%100.0%100.0%—
Research & Development220.18M256.39M242.91M192.3M150.15M
Selling, General & Admin74.11M79.31M71.67M65.21M56.78M
Operating Expenses294.28M321.4M327.83M273.22M194.57M
Depreciation & Amortization10.45M14.3M14.2M13.64M12.36M
EBITDA(171.6M)(326.12M)(313.07M)(243.33M)(177.45M)
EBITDA Margin-150.4%-209050.6%-329543.2%-1106031.8%—
Operating Income(180.19M)(335.54M)(327.74M)(273.2M)(206.93M)
Operating Margin-157.9%-215087.2%-344986.3%-1241813.6%—
Interest Income1.71M4.57M18.31M20.15M19.29M
Interest Expense000181K1.08M
Other Income / Expenses(1.86M)(4.88M)472K16.05M16.05M
Income Before Tax(182.05M)(340.41M)(327.27M)(257.15M)(190.89M)
Pre-Tax Margin-159.6%-218214.1%-344489.5%-1168850.0%—
Income Tax Expense000443K0
Net Income(182.05M)(340.41M)(327.27M)(257.59M)(190.89M)
Net Margin-159.6%-218214.1%-344489.5%-1170863.6%—
EPS (Basic)(1.34)(2.38)(2.09)(1.32)(0.87)
EPS (Diluted)(1.34)(2.38)(2.09)(1.32)(0.87)
Weighted Avg Shares135.82M143.15M156.93M194.81M220.62M
Weighted Avg Shares (Diluted)135.82M143.15M156.93M194.81M220.62M

Allogene Therapeutics, Inc.

NASDAQ:ALLO

Intrinsic Alpha fair value

Locked

Current Price

$0.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.